Scancell Hldgs 

$0.22
20
+$0.05+31.49% Monday 13:30

Statistics

Day High
0.22
Day Low
0.22
52W High
0.22
52W Low
0.12
Volume
-
Avg. Volume
-
Mkt Cap
231.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29JanExpected
Q4 2022
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-1.4
-1.03
-0.66
-0.3
Expected EPS
N/A
Actual EPS
-0.609645221573542

Financials

-256.26%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
12.55MRevenue
-32.17MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SCNLF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap17.99B
Moderna is a leader in mRNA technology, similar to Scancell's focus on novel immunotherapies, making them direct competitors in the vaccine and therapeutic space.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech competes in the development of novel immunotherapies for cancer and infectious diseases, directly aligning with Scancell's research focus.
Novavax
NVAX
Mkt Cap1.32B
Novavax is involved in the development of vaccines for infectious diseases, competing with Scancell's infectious disease vaccine programs.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a biopharmaceutical company that develops drugs for infectious diseases, directly competing with Scancell's therapeutic development.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on human therapeutics, including treatments for cancer and inflammation, overlapping with Scancell's therapeutic areas.
Pfizer
PFE
Mkt Cap149.77B
Pfizer develops vaccines and therapeutics for various diseases, competing with Scancell in the broader pharmaceutical and biotech industry.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and therapeutics, similar to Scancell's focus areas.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca is involved in the development of vaccines and cancer treatments, making it a competitor in Scancell's key research areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals focuses on developing monoclonal antibodies, a technology that competes with Scancell's immunotherapy approaches.
Merck
MRK
Mkt Cap277.02B
Merck & Co. develops vaccines and cancer immunotherapies, directly competing with Scancell's product development pipeline.

About

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Show more...
CEO
Dr. Phillip John L'Huillier MBA, Ph.D.
Employees
61
Country
United Kingdom
ISIN
GB00B63D3314

Listings

0 Comments

Share your thoughts

FAQ

What is Scancell Hldgs stock price today?
The current price of SCNLF is $0.22 USD — it has increased by +31.49% in the past 24 hours. Watch Scancell Hldgs stock price performance more closely on the chart.
What is Scancell Hldgs stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scancell Hldgs stocks are traded under the ticker SCNLF.
What is Scancell Hldgs market cap?
Today Scancell Hldgs has the market capitalization of 231.84M
When is the next Scancell Hldgs earnings date?
Scancell Hldgs is going to release the next earnings report on October 23, 2026.
What were Scancell Hldgs earnings last quarter?
SCNLF earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scancell Hldgs revenue for the last year?
Scancell Hldgs revenue for the last year amounts to 12.55M USD.
What is Scancell Hldgs net income for the last year?
SCNLF net income for the last year is -32.17M USD.
How many employees does Scancell Hldgs have?
As of May 06, 2026, the company has 61 employees.
In which sector is Scancell Hldgs located?
Scancell Hldgs operates in the Health & Wellness sector.
When did Scancell Hldgs complete a stock split?
The last stock split for Scancell Hldgs was on July 26, 2011 with a ratio of 10:1.
Where is Scancell Hldgs headquartered?
Scancell Hldgs is headquartered in Oxford, United Kingdom.